ÀÌÁÖÈ£
°£À̽ļ¾ÅÍÀå
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : °£Àå, °£¾Ï, ¾Ï ¸é¿ªÄ¡·á
Á÷
ˤ
: ºÎ±³¼ö(°£À̽ļ¾ÅÍÀå)
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
7
ÇØ¿Ü
Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition
6
ÇØ¿Ü
Genetic Predisposition of Hand-Foot Skin Reaction After Sorafenib Therapy in Patients With Hepatocellular Carcinoma
5
ÇØ¿Ü
Effects of Genomic Changes in Hepatitis B Virus on Postoperative Recurrence and Survival in Patients with Hepatocellular Carcinoma
4
ÇØ¿Ü
Synergistic Effects of A1896, T1653 and T1762/A1764 Mutations in Genotype C2 Hepatitis B Virus on Development of Hepatocellular Carcinoma
3
±¹³»
Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Induced by Celecoxib and Anti-tuberculosis Drugs
2
±¹³»
Osler-Weber-Rendu disease presenting with hepatocellular carcinoma: radiologic and genetic findings
1
±¹³»
Drug rash with eosinophilia and systemic symptoms syndrome following cholestatic hepatitis A: a case report
1
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729